In vitro activity of tigecycline against Acinetobacter baumannii strains isolated from nosocomial infections

Turkish Journal of Medical Sciences

Volumn 38, Issue 6, 2008, Pages 583-586

  Akinci, Esragül ^a   Mumcuoǧlu, Ipek ^a   Öngürü, Pinar ^a   Bayazit, F Nurhayat ^a   Ersoy Şen, Sevinç ^a   Erbay, Ayşe ^a   Balaban, Neriman ^a   Bodur, Hürrem ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Acinetobacter; Antibiotic; Resistance; Tigecycline

Indexed keywords

ACINETOBACTER; ACTIVE AGENTS; BROAD SPECTRUMS; IN VITRO; IN VITRO ACTIVITIES; INFECTED PATIENTS; MINIMUM INHIBITORY CONCENTRATIONS; MORTALITY RATES; MULTIPLE DRUG RESISTANCES; NETILMICIN; RESISTANCE; TIGECYCLINE;

ANTIBIOTICS;

NETILMICIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; HOSPITAL INFECTION; HOSPITAL PATIENT; IN VITRO STUDY; MEDICAL DOCUMENTATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN;

EID: 56849124651     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hawkey P, Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 2007; 13: 354-62.
2. Fraise AP. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance? J Infect 2006; 53: 293-300. Epub 2006 Jul 28.
3. Clinical and Laboratory Standards Institute. Performance antimicrobial susceptibility testing M100-S16. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2006.
4. Insa R, Cercenado E, Goyanes MJ, Morente A, Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007; 59: 583-5.
5. Pachón-Ibáñez ME, Jiménez-Mejías ME, Pichardo C, Llanos AC, Pachón J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-81.
6. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87.
7. Van Looveren M, Goossens H; ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684-704.
8. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-8.
9. Akinci E, Colpan A, Bodur H, Balaban N, Erbay A. Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections. J Hosp Infect 2005; 59: 317-23.
10. Baran G, Erbay A, Bodur H, Onguru P, Akinci E, Balaban N et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2007 May 18; [Epub ahead of print].
11. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-27.
12. Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int J Infect Dis 2004; 8: 284-91.
13. Kuo LC, Teng LJ, Yu CJ, Ho SW, Hsueh PR. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J Clin Microbiol 2004; 42: 1759-63.
14. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
15. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26: 704-14.
16. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM et al. 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005; 5: 88.
17. Taccone FS, Rodriguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006; 25: 257-60.